A Swedish database of over 35,000 individuals found better cardiovascular outcomes when ezetimibe was added earlier to statin therapy for secondary prevention. Study authors deemed ezetimibe a ...

Please provide your email address to receive an email when new articles are posted on . Obicetrapib plus ezetimibe lowered LDL nearly 50% vs. placebo in patients with high atherosclerotic risk.

% differences compared with placebo or indicated statin are based on differences of individual least square means for LDL-C, HDL-C, non-HDL-C and apoB, and on differences of individual medians or ...

A strategy that combines high-intensity statin therapy with ezetimibe early after myocardial infarction results in a lower risk of recurrent events when contrasted with approaches that start ...

A combination of simvastatin and ezetimibe (Vytorin) lowered cholesterol better than simvastatin alone, but it had no effect on arterial plaque in a major clinical trial. As a result, cardiologists ...

Please provide your email address to receive an email when new articles are posted on . Lerodalcibep, an investigational PCSK9 inhibitor, decreased LDL cholesterol on top of existing oral agents ...

Adding ezetimibe (Zetia) therapy to statins early after a heart attack improved outcomes, Swedish national records suggested. With statins almost universally used in this setting, people who also got ...